| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.60▼ | 1.61▼ | 1.62▼ | 1.47▲ | 1.45▲ |
| MA10 | 1.61▼ | 1.63▼ | 1.57▲ | 1.44▲ | 1.37▲ |
| MA20 | 1.61▼ | 1.57▲ | 1.53▲ | 1.43▲ | 1.33▲ |
| MA50 | 1.63▼ | 1.50▲ | 1.47▲ | 1.39▲ | 2.23▼ |
| MA100 | 1.57▲ | 1.46▲ | 1.43▲ | 1.36▲ | 6.96▼ |
| MA200 | 1.52▲ | 1.43▲ | 1.41▲ | 2.04▼ | 20.39▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.002▼ | -0.002▼ | 0.008▲ | 0.013▲ | 0.132▲ |
| RSI | 34.582▼ | 53.814▲ | 59.482▲ | 65.148▲ | 46.333▼ |
| STOCH | 46.667 | 46.577 | 71.867 | 57.671 | 55.209 |
| WILL %R | -100.000▼ | -53.488 | -52.273 | -28.095 | -19.213▲ |
| CCI | -256.962▼ | -9.158 | 49.762 | 235.930▲ | 143.262▲ |
|
Wednesday, August 06, 2025 01:17 PM
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated ...
|
|
Tuesday, July 01, 2025 07:00 AM
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/08/25 | 1.50 | 1.6994 | 1.50 | 1.59 | 1,483,251 |
| 14/08/25 | 1.49 | 1.515 | 1.47 | 1.48 | 707,643 |
| 13/08/25 | 1.43 | 1.519 | 1.42 | 1.49 | 630,224 |
| 12/08/25 | 1.41 | 1.42 | 1.36 | 1.41 | 588,135 |
| 11/08/25 | 1.45 | 1.46 | 1.39 | 1.40 | 515,002 |
| 08/08/25 | 1.46 | 1.5499 | 1.415 | 1.44 | 496,777 |
| 07/08/25 | 1.39 | 1.50 | 1.37 | 1.45 | 1,138,406 |
| 06/08/25 | 1.39 | 1.41 | 1.35 | 1.38 | 385,648 |
| 05/08/25 | 1.39 | 1.45 | 1.39 | 1.41 | 491,754 |
| 04/08/25 | 1.35 | 1.41 | 1.325 | 1.39 | 380,821 |
|
|
||||
|
|
||||
|
|